General Dermatology

Dermatology Times is recapping our top expert interviews from the month of October.

A pilot study monitored the disease management, technical challenges, and overall benefits for chronic spontaneous urticaria.

Personalized treatment strategies for infectious skin diseases are being developed using AI algorithms that analyze individual patient data.

A study of the new cleanser included diverse participants, ensuring it is suitable for various skin types and sensitivities.

Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.

The late-breaking data will be presented at ACAAI’s annual Scientific Meeting.

The application of a clinically validated moisturizer before mask-wearing was shown to significantly improve skin barrier function and reduce irritation.

Click here to answer today’s poll and read more about the perception of telehealth treatment in dermatology.

Researchers behind a recent study found that patients with liver disease had a significantly higher prevalence of chronic pruritus.

The multicenter trial reported high response rates and low risk of discontinuation for treating long-term chronic inducible urticaria.

Developed by a panel of global dermatology experts, the SQS addresses the multifaceted nature of skin quality.

Although further research is still needed, dermatologists and patients are generally satisfied with teledermatology treatment.

The app demonstrated high sensitivity (92.0%) and specificity (95.5%) in identifying skin changes through a controlled testing environment.

Efinaconazole demonstrated enhanced efficacy in treating nail fungal infections, thanks to its high penetration capability and low keratin binding.

Dermatology offers the power of choice, and it can be exactly what you make of it, writes our Fall Editor in Chief Raj Chovatiya, MD, PhD.

Join Dermatology Times in honoring World Mental Health Day on Oct 10, 2024.

The expanded dosage aims to provide healthcare providers with greater flexibility in treating larger or multiple areas affected by AK.

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

Dermatology Times is looking back on the top stories in dermatology from the month of September.

Dermatology Times is recapping our top expert interviews from the month of September.

In recent years, there has been a noticeable rise in diagnoses of sexually transmitted infections, often which present with skin findings.

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

Learn more about the latest in dermatology from Sheila Fallon Friedlander, MD; Melodie Young, MSN, ANP-c; Raj Chovatiya, MD, PhD, MSCI; Julie Harper, MD; and Matthew Zirwas, MD.

Review cutaneous signs and symptoms of HAE that may enhance early diagnosis and treatment.

Lim discusses support for underserved communities, including dermatology training for Pacific Island Nations.